Optina Diagnostics Closes an Oversubscribed Series-A Round of CA$24.8 million
PR92673
MONTREAL, Oct. 28, 2021 /PRNewswire=KYODO JBN/ --
-- This round was led by DigitalDx Ventures and supported by Boehringer
Ingelheim Venture Fund
-- Other investors include Desjardins Capital, Hike Ventures, Advisors Fund,
MEDTEQ+ and Biomed Propulsion (participative debt)
-- New funding will support the development of Optina's Retinal Deep
Phenotyping(TM) platform
-- It will also support Optina's pivotal study for the FDA regulatory
submission of the awAIr(TM) cerebral amyloid status test for Alzheimer's
disease detection, aligning the platform with novel therapeutic approvals
Optina, an innovative diagnostics company, leader in Retinal Imaging, Brain
Health and Systemic Disease detection, announced today the closing of a CA$24.8
million Series-A round of funding.
Photo -
Photo -
Optina's Retinal Deep Phenotyping(TM) platform obtained FDA Breakthrough Device
Designation status in 2019 for its non-invasive and more accessible test to
improve diagnosis accuracy and the management of patients undergoing evaluation
for Alzheimer's disease (AD). The Series A's primary focus is to support the
pivotal study for Optina's awAIr(TM) cerebral amyloid status test when AD is
suspected and will also support the platform development for early detection of
systemic diseases.
"DigitalDx is honored to have led a successful round for Optina Diagnostics. At
DigitalDx we believe the recent technological advances in health data capture
enabled by artificial intelligence (AI) could dramatically impact our ability
to diagnose illness earlier, potentially drastically improve patient outcomes
and save our healthcare system billions of dollars and could redefine the way
we create value in healthcare," says Michele Colucci Founder & CEO of DigitalDx
Ventures.
"The Boehringer Ingelheim Venture Fund recognizes the potential of the Optina
technology for capturing a variety of data types at extremely high resolution
through a possibly faster and simpler non-invasive eye scan. This technology
could be tremendously valuable for advancing efforts in R&D biomarker
development. We are excited that Optina will continue to develop their platform
in multiple areas and strive to bring meaningful health outcomes for patients,"
said Debbie Lin, Ph.D., Executive Director of Digital Health Investments,
Boehringer Ingelheim Venture Fund.
Funds will also be used to accelerate the deployment of additional clinical
study sites with the installation of Optina's Retinal Deep Phenotyping(TM)
platform at leading institutions in the United States, Canada, and Europe.
"We are eager to put this investment to work. Optina is at the forefront of
Systemic Diseases and Brain Health diagnosis and clinical experts are
advocating for novel objective tools for early diagnosis and monitoring of
at-risk patients for these underserved disease areas. This funding could allow
us to make a significant difference by changing mindsets when it comes to Brain
Health and hopefully ease millions of worried patients around the world by
detecting the causes of their cognitive impairment and providing them access to
novel therapeutics," said David Lapointe, CEO Optina Diagnostics.
About Optina Diagnostics
Optina Diagnostics is a Montreal-based company focused on changing mindsets
when it comes to Brain Health and systemic diseases. With a first application
in the early diagnosis of Alzheimer's, Optina challenges the status quo by
providing an accurate, simple, and non-invasive optical test to understand the
age-related sources of memory loss, empowering millions. optinadx.com
About DigitalDx Ventures
DigitalDx Ventures is a woman-owned Venture Capital fund in Silicon Valley
supporting companies that diagnose illness earlier, less invasively, more
accurately and less expensively enabled by artificial intelligence and data.
The Fund is committed to producing a triple bottom line: superior financial
returns, diversity and access to healthcare for all. There are currently 8
companies in the portfolio providing game changing diagnostics in Alzheimer's
diagnosis, kidney health, breast cancer, mental health, maternal health,
patient monitoring and multi cancer screening.
About Boehringer Ingelheim Venture Fund
The Boehringer Ingelheim Venture Fund is the strategic venture fund of
Boehringer Ingelheim Corporation. Since 2010, we invest in pioneering science
that offers the potential to provide a significant benefit for our patients.
Innovation is not restricted by geography; therefore, we invest worldwide.
About Desjardins Capital
Over 45 years strong, Desjardins Capital (https://c212.net/c/link/?t=0&l=en&o=3338357-1&h=1507816921&u=https%3A%2F%2Fwww.desjardinscapital.com%2F&a=Desjardins+Capital)
has a mission to value, support and nurture the best of Quebec
entrepreneurship. With assets under management of C$2.8 billion as of June 30,
2021, Desjardins Capital helps contribute to the longevity of more than 610
companies, cooperatives and funds in various sectors from across Quebec. In
addition to helping to maintain and create many thousands of jobs, this
subsidiary of Desjardins Group (https://c212.net/c/link/?t=0&l=en&o=3338357-1&h=3645944965&u=https%3A%2F%2Fwww.desjardins.com%2F&a=Desjardins+Group) offers business owners access to a large business network and supports their
business growth. For more information, visit our website, desjardinscapital.com
Marie-Claude Marchand, Chief Commercial Officer & Communications, Optina
Diagnostics Inc., +1 514.727.1571, mcmarchand@optinadx.com
SOURCE Optina Diagnostics
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。